Clinical trials: Bacteriophages
Diarrhea
Antibacterial Treatment Against Diarrhea in Oral Rehydration Solution
This study hopes to demonstrate the potentials of a new form of therapy for childhood diarrhea, a major cause of morbidity and deaths in Bangladesh and other developing countries, and thus a priority for improving child health.
- Trial name
- NCT00937274
- Testing
- T4 phage cocktail test, Commercial T4 phage cocktail, standard oral rehydration solution (ORS)
- Where
- Bangladesh
- Volunteers
- 120 people
- Sponsor
- Société des Produits Nestlé (SPN)
Bone and Joint Infection, Prosthetic Joint Infection
Phage Safety Retrospective Cohort Study
The aim of this study is to determine the imputability of adverse events in patients who have had phage therapy for the treatment of their bone or joint or implant infection, in order to find out whether these adverse effects are…
- Trial name
- PHASACO-retro (NCT04724603)
- Testing
- patients having had avderse event after phagotherapy for bone or joint or implant infection
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Hospices Civils de Lyon
Bone Infection
Avis-PHAGEinLYON Clinic
Avis-PHAGEinLYON Clinic study is a single site non-interventional retrospective and prospective study, initiated by the Hospices Civils de Lyon.
- Trial name
- NCT05883995
- Testing
- Phage therapy requests
- Where
- France
- Volunteers
- 1,500 people
- Sponsor
- Hospices Civils de Lyon
Microbiota, Bacteriophages
Probiotics After Discharge
The influence of the preterm gut microbiota in health and disease has been well established. However, relatively little is known about how the microbiome changes after discharge and its relationship with growth, health and…
- Conditions
- Microbiota, Bacteriophages, Infantile Colic, Growth
- Trial name
- PAD (NCT02695784)
- Testing
- Probiotic Continuation
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic
The purpose of the expanded access program is to allow physicians to provide treatment with investigational drug, AB-PA01, for patients with serious or immediately life-threatening Pseudomonas aeruginosa infections, for which no…
- Trial name
- NCT03395743
- Testing
- AB-PA01
- Sponsor
- Armata Pharmaceuticals, Inc.
Prosthetic Joint Infections of Hip
Bacteriophage Therapy for Morganella Morganii Prosthetic Joint Infection
This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage drug product to treat and prevent the recurrence of a Morganella morganii prosthetic joint infection of the hip.
- Trial name
- PHAGE-MOM-001 (NCT06814756)
- Testing
- phage therapy
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of Calgary
Urinary Tract Infections, Transplant-Related Disorder
Treatment Chronic UTI Post Kidney Transplant
Urinary tract infections (UTIs) with extended-spectrum -lactamase (ESBL)-positive Enterobacteriums (ESBL-E) are a common infectious complication of renal transplant recipients, with 10% of patients suffering from UTIs with ESBL-E…
- Trial name
- NCT05967130
- Testing
- Phage
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Prosthetic Joint Infections of Hip, Staphylococcus Aureus Infection
Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection
This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage cocktail to treat and prevent the recurrence of a methicillin-susceptible Staphylococcus aureus prosthetic joint infection…
- Trial name
- PHAGE-2024-01 (NCT06456424)
- Testing
- Phage therapy
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of Calgary
Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease
Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria
About 10 people with cystic fibrosis (CF) and persistent Nontuberculosis mycobacteria (NTM) infection despite treatment will be screened to find out if their NTM infection has at least one mycobacteriophage that is effective in…
- Conditions
- Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections
- Trial name
- POSTSTAMP (NCT06262282)
- Testing
- mycobacteriophage
- Where
- 18 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Jewish Health
Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic
The purpose of the expanded access program is to allow physicians to provide treatment with investigational drug, AB-SA01, for patients with serious or immediately life-threatening Staphylococcus aureus infections, for which no…
- Trial name
- NCT03395769
- Testing
- AB-SA01
- Sponsor
- Armata Pharmaceuticals, Inc.
Acne
Evaluation and Detection of Facial Propionibacterium Acnes Bacteria and Phage
This multi-center, outpatient study will extract and evaluate the presence of facial P. acnes bacteria and phage strains using pore strips on up to 400 human subjects.
- Trial name
- NCT03009903
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- MBcure Ltd
HIV Infections
The Use of Bacteriophage Phi X174 to Assess the Immune Competence of HIV-Infected Patients In Vivo
The objective of this study is to evaluate the safety and utility of bacteriophage phi X174 immunization as a tool to assess the immune competence of HIV-infected patients at different stages of disease in vivo, and to assess the…
- Trial name
- NCT00001540
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Primary Immune Deficiency Diseases
Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)
This protocol is designed to ascertain whether the bacteriophage 0X174 neoantigen is safe and effective as an antigen used in the evaluation of primary and secondary immune responses.
- Trial name
- Bacteriophage (NCT01617122)
- Testing
- Bacteriophage OX174
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Genetic Predisposition to Disease, Celiac Disease
Gluten-free Diet in Gluten-genetically Predisposed Subjects
Undetected or untreated CD may cause severe complications later in life, such as autoimmune disorders. It is recommended for subjects with autoimmune diseases or at risk for CD to be screened for CD and to repeat serological…
- Trial name
- NCT00677495
- Testing
- Gluten-free diet
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS Burlo Garofolo
Musculoskeletal Infection, Chronic Rhinosinusitis (Diagnosis)
Establishing Personalized Phage Therapy and Its Comparative Cost in Difficult-to-treat Infections (EPHICACI)
EPHICACI is a multicenter, prospective study that continues and expands the monocentric PHAGEFORCE registry initiated at UZ Leuven.
- Conditions
- Musculoskeletal Infection, Chronic Rhinosinusitis (Diagnosis), Persistent Bacteremia, Pulmonary Infection
- Trial name
- EPHICACI (NCT06368388)
- Testing
- Prospective data collection phage therapy, Prospective data collection standard-of-care
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection
Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection
This study aims to use mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with…
- Trial name
- NCT07228702
- Testing
- Mycobacteriophage Muddy_HRMN0052, Amikacin Injection, Clofazimine
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Vancouver Coastal Health
Prosthetic Joint Infections of Hip, Bacteriophage Therapy
Bacteriophage Therapy for Staphylococcus Lugdunensis Prosthetic Joint Infection
This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage drug product to treat and prevent the recurrence of a Staphylococcus lugdunensis prosthetic joint infection of the hip.
- Trial name
- NCT07461337
- Testing
- Five phage anti-Staphylococcus aureus bacteriophage cocktail
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of Calgary
Cystic Fibrosis
Bacteriophage Effects on Pseudomonas Aeruginosa
Pulmonary phage therapy to treat bacterial infections of the respiratory tract have been investigated in animals. The aim of the present study is to evaluate the efficacy of bacteriophages in infecting Pseudomonas aeruginosa (PA)…
- Trial name
- MUCOPHAGES (NCT01818206)
- Testing
- Collection of induced sputum in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
- Where
- France
- Volunteers
- 59 people
- Sponsor
- University Hospital, Montpellier
Feeding Patterns, Microbial Colonization
Prephage - Faecal Bacteriophage Transfer for Enhanced Gastrointestinal Tract Maturation in Preterm Infants - Donor Study
PrePhage - Fecal bacteriophage transfer for enhanced gastrointestinal tract maturation in preterm infants This pilot triol has the primary goal of demonstrating the safety of transferring viruses and proteins from healthy term…
- Trial name
- NCT05272566
- Where
- Denmark
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Bacterial Infections
Bacteriophage Therapy of Difficult-to-treat Infections
A retrospective, observational analysis of the first one hundred consecutive cases of bacteriophage therapy of difficult-to-treat infections, facilitated by a Belgian consortium.
- Trial name
- BT100 (NCT05498363)
- Testing
- Bacteriophage therapy
- Volunteers
- 100 people
- Sponsor
- Queen Astrid Military Hospital